These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 16675563)

  • 1. Genomic alterations in human malignant glioma cells associate with the cell resistance to the combination treatment with tumor necrosis factor-related apoptosis-inducing ligand and chemotherapy.
    Li YC; Tzeng CC; Song JH; Tsia FJ; Hsieh LJ; Liao SJ; Tsai CH; Van Meir EG; Hao C; Lin CC
    Clin Cancer Res; 2006 May; 12(9):2716-29. PubMed ID: 16675563
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of death receptor 4 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in gliomas.
    Elias A; Siegelin MD; Steinmüller A; von Deimling A; Lass U; Korn B; Mueller W
    Clin Cancer Res; 2009 Sep; 15(17):5457-65. PubMed ID: 19706813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenethyl isothiocyanate sensitizes glioma cells to TRAIL-induced apoptosis.
    Lee DH; Kim DW; Lee HC; Lee JH; Lee TH
    Biochem Biophys Res Commun; 2014 Apr; 446(4):815-21. PubMed ID: 24491546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5.
    Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
    Int J Oncol; 2015 Aug; 47(2):506-16. PubMed ID: 26044191
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Direct stimulation of apoptotic signaling by soluble Apo2l/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells.
    Pollack IF; Erff M; Ashkenazi A
    Clin Cancer Res; 2001 May; 7(5):1362-9. PubMed ID: 11350907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
    Koschny R; Holland H; Sykora J; Haas TL; Sprick MR; Ganten TM; Krupp W; Bauer M; Ahnert P; Meixensberger J; Walczak H
    Clin Cancer Res; 2007 Jun; 13(11):3403-12. PubMed ID: 17545549
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector.
    Rubinchik S; Yu H; Woraratanadharm J; Voelkel-Johnson C; Norris JS; Dong JY
    Cancer Gene Ther; 2003 Nov; 10(11):814-22. PubMed ID: 14605667
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines.
    Keane MM; Ettenberg SA; Nau MM; Russell EK; Lipkowitz S
    Cancer Res; 1999 Feb; 59(3):734-41. PubMed ID: 9973225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human melanoma cells selected for resistance to apoptosis by prolonged exposure to tumor necrosis factor-related apoptosis-inducing ligand are more vulnerable to necrotic cell death induced by cisplatin.
    Zhang XD; Wu JJ; Gillespie S; Borrow J; Hersey P
    Clin Cancer Res; 2006 Feb; 12(4):1355-64. PubMed ID: 16489094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin down-regulation of cellular Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human melanoma cells.
    Song JH; Song DK; Herlyn M; Petruk KC; Hao C
    Clin Cancer Res; 2003 Sep; 9(11):4255-66. PubMed ID: 14519653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced apoptosis following treatment with TRA-8 anti-human DR5 monoclonal antibody and overexpression of exogenous Bax in human glioma cells.
    Kaliberov S; Stackhouse MA; Kaliberova L; Zhou T; Buchsbaum DJ
    Gene Ther; 2004 Apr; 11(8):658-67. PubMed ID: 14973547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genistein enhances proteasomal degradation of the short isoform of FLIP in malignant glioma cells and thereby augments TRAIL-mediated apoptosis.
    Siegelin MD; Siegelin Y; Habel A; Gaiser T
    Neurosci Lett; 2009 Apr; 453(2):92-7. PubMed ID: 19356600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective combination therapy for malignant glioma with TRAIL-secreting mesenchymal stem cells and lipoxygenase inhibitor MK886.
    Kim SM; Woo JS; Jeong CH; Ryu CH; Lim JY; Jeun SS
    Cancer Res; 2012 Sep; 72(18):4807-17. PubMed ID: 22962275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The XIAP inhibitor Embelin enhances TRAIL-mediated apoptosis in malignant glioma cells by down-regulation of the short isoform of FLIP.
    Siegelin MD; Gaiser T; Siegelin Y
    Neurochem Int; 2009 Nov; 55(6):423-30. PubMed ID: 19409438
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo.
    Nagane M; Pan G; Weddle JJ; Dixit VM; Cavenee WK; Huang HJ
    Cancer Res; 2000 Feb; 60(4):847-53. PubMed ID: 10706092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells.
    Uzzaman M; Keller G; Germano IM
    J Neurosurg; 2007 Apr; 106(4):646-51. PubMed ID: 17432717
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells.
    Knight MJ; Riffkin CD; Muscat AM; Ashley DM; Hawkins CJ
    Oncogene; 2001 Sep; 20(41):5789-98. PubMed ID: 11593384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo.
    Fulda S; Wick W; Weller M; Debatin KM
    Nat Med; 2002 Aug; 8(8):808-15. PubMed ID: 12118245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation.
    Yoon MJ; Kang YJ; Kim IY; Kim EH; Lee JA; Lim JH; Kwon TK; Choi KS
    Carcinogenesis; 2013 Aug; 34(8):1918-28. PubMed ID: 23615398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.